Abetimus

Identification

Generic Name
Abetimus
DrugBank Accession Number
DB06662
Background

Abetimus was developed by La Jolla Pharmaceuticals as an immunosuppressant but was never marketed in American or Europe despite application for marketing authorization in the mid-2000s.

Type
Biotech
Groups
Investigational
Biologic Classification
Nucleic Acid Based Therapies
Oligonucleotides
Synonyms
  • Abetimus

Pharmacology

Indication

Investigated for use/treatment in kidney disease and systemic lupus erythematosus.

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Abetimus.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Abetimus.
Adenovirus type 7 vaccine liveThe risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Abetimus.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Abetimus.
AlefaceptThe risk or severity of adverse effects can be increased when Alefacept is combined with Abetimus.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Abetimus.
AltretamineThe risk or severity of adverse effects can be increased when Altretamine is combined with Abetimus.
AmsacrineThe risk or severity of adverse effects can be increased when Amsacrine is combined with Abetimus.
AnakinraThe risk or severity of adverse effects can be increased when Anakinra is combined with Abetimus.
Anthrax immune globulin humanThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Abetimus.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Product Ingredients
IngredientUNIICASInChI Key
Abetimus sodiumF5Y7739G6U169147-32-4Not applicable
International/Other Brands
Riquent

Categories

ATC Codes
L04AA22 — Abetimus
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
P3UVQ22SHK
CAS number
167362-48-3

References

General References
  1. Authors unspecified: Abetimus: Abetimus sodium, LJP 394. BioDrugs. 2003;17(3):212-5. [Article]
  2. Wallace DJ: Clinical and pharmacological experience with LJP-394. Expert Opin Investig Drugs. 2001 Jan;10(1):111-7. [Article]
RxNav
1311600
Wikipedia
Abetimus

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentAutoimmune Diseases / Immunologic Diseases / Lupus Glomerulonephritis / Nephritis, Lupus / Systemic Lupus Erythematosus (SLE)1
3TerminatedTreatmentNephritis, Lupus / Systemic Lupus Erythematosus (SLE)1
2WithdrawnDiagnosticSystemic Lupus Erythematosus (SLE)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Drug created on March 19, 2008 16:46 / Updated on February 21, 2021 18:52